[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRRgh_Klj_NDsJlYN0185E_laCbDEWHMdszAUEGODc7g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"University Hospital Freiburg",[4],93,false,16,12,103788,2,62,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Liver Cirrhosis",5,{"name":18,"count":11},"Therapy-resistant Depression",{"name":20,"count":11},"Portal Hypertension",{"name":22,"count":11},"Myelodysplastic Syndromes",{"name":24,"count":11},"Acute Myeloid Leukemia",{"name":26,"count":11},"Corneal Transplantation",{"name":28,"count":11},"Non-Cirrhotic Portal Hypertension",{"name":30,"count":11},"Retinopathy of Prematurity (ROP)",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06830421","Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients","2029-08-31","R-MP and Procarbazine maintenance",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,71,89,111,140,158,176,203,221,239,268,286,311,338,362,389,407,440,458,476,494,512,534,555,581,606,648,670,694,719,737,755,773,791,809,837,855,873,891,914,940,958,976,1001,1027,1052,1078,1102,1129,1153,1180,1206],{"intervention":36,"totalTrials":46,"cells":47},1,{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":67,"NA":69},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":50},[],{"trials":54,"activeCount":50},[],{"trials":56,"activeCount":46,"soonestReadout":35},[57],{"nctId":33,"briefTitle":34,"status":58,"phases":59,"primaryCompletion":35,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":65},"RECRUITING",[41],"2031-08-31","2023-08-09",340,[64],"Primary Central Nervous System Lymphoma",[36,66],"R-MTX\u002FAraC (MARTA) induction followed by consolidating HCT-ASCT",{"trials":68,"activeCount":50},[],{"trials":70,"activeCount":50},[],{"intervention":66,"totalTrials":46,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":85,"NA":87},{"trials":74,"activeCount":50},[],{"trials":76,"activeCount":50},[],{"trials":78,"activeCount":50},[],{"trials":80,"activeCount":46,"soonestReadout":35},[81],{"nctId":33,"briefTitle":34,"status":58,"phases":82,"primaryCompletion":35,"completion":60,"start":61,"enrollment":62,"conditions":83,"interventions":84},[41],[64],[36,66],{"trials":86,"activeCount":50},[],{"trials":88,"activeCount":50},[],{"intervention":90,"totalTrials":46,"cells":91},"Mycophenolate Mofetil 2x 1g",{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":109},{"trials":93,"activeCount":50},[],{"trials":95,"activeCount":50},[],{"trials":97,"activeCount":50},[],{"trials":99,"activeCount":50},[],{"trials":101,"activeCount":50},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"conditions":107,"interventions":108},"NCT00411515","A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty","COMPLETED",[42],[26],[90],{"trials":110,"activeCount":50},[],{"intervention":112,"totalTrials":46,"cells":113},"ezetimibe",{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":118,"PHASE3":120,"PHASE4":122,"NA":138},{"trials":115,"activeCount":50},[],{"trials":117,"activeCount":50},[],{"trials":119,"activeCount":50},[],{"trials":121,"activeCount":50},[],{"trials":123,"activeCount":50},[124],{"nctId":125,"briefTitle":126,"status":105,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"NCT01384058","Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes",[42],"2010-05","2010-06","2007-11",41,[133,134],"Diabetes Mellitus Type 2","Hypercholesterolemia",[112,136,137],"simvastatin","Ezetimibe 10\u002FSimvastatin 20",{"trials":139,"activeCount":50},[],{"intervention":136,"totalTrials":46,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":50},[],{"trials":145,"activeCount":50},[],{"trials":147,"activeCount":50},[],{"trials":149,"activeCount":50},[],{"trials":151,"activeCount":50},[152],{"nctId":125,"briefTitle":126,"status":105,"phases":153,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":154,"interventions":155},[42],[133,134],[112,136,137],{"trials":157,"activeCount":50},[],{"intervention":137,"totalTrials":46,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":174},{"trials":161,"activeCount":50},[],{"trials":163,"activeCount":50},[],{"trials":165,"activeCount":50},[],{"trials":167,"activeCount":50},[],{"trials":169,"activeCount":50},[170],{"nctId":125,"briefTitle":126,"status":105,"phases":171,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":172,"interventions":173},[42],[133,134],[112,136,137],{"trials":175,"activeCount":50},[],{"intervention":177,"totalTrials":46,"cells":178},"Basiliximab, Tacrolimus, MMF, Prednisolon",{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":201},{"trials":180,"activeCount":50},[],{"trials":182,"activeCount":50},[],{"trials":184,"activeCount":50},[],{"trials":186,"activeCount":50},[],{"trials":188,"activeCount":50},[189],{"nctId":190,"briefTitle":191,"status":105,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT00724022","Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation",[42],"2014-07","2008-06",600,[197],"Disorder Related to Renal Transplantation",[177,199,200],"Basiliximab, Tacrolimus, MMF","Tacrolimus, MMF, rATG",{"trials":202,"activeCount":50},[],{"intervention":199,"totalTrials":46,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":219},{"trials":206,"activeCount":50},[],{"trials":208,"activeCount":50},[],{"trials":210,"activeCount":50},[],{"trials":212,"activeCount":50},[],{"trials":214,"activeCount":50},[215],{"nctId":190,"briefTitle":191,"status":105,"phases":216,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":217,"interventions":218},[42],[197],[177,199,200],{"trials":220,"activeCount":50},[],{"intervention":200,"totalTrials":46,"cells":222},{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":237},{"trials":224,"activeCount":50},[],{"trials":226,"activeCount":50},[],{"trials":228,"activeCount":50},[],{"trials":230,"activeCount":50},[],{"trials":232,"activeCount":50},[233],{"nctId":190,"briefTitle":191,"status":105,"phases":234,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":235,"interventions":236},[42],[197],[177,199,200],{"trials":238,"activeCount":50},[],{"intervention":240,"totalTrials":46,"cells":241},"0.1% Octenidine with 30% 1-propanol and 45% 2-propanol",{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":266},{"trials":243,"activeCount":50},[],{"trials":245,"activeCount":50},[],{"trials":247,"activeCount":50},[],{"trials":249,"activeCount":50},[],{"trials":251,"activeCount":50},[252],{"nctId":253,"briefTitle":254,"status":105,"phases":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":264},"NCT00515151","Prevention of Catheter-Associated Infection With the Skin Disinfectant Octenidine Dihydrochloride",[42],"2005-04","2002-05",400,[260,261,262,263],"Catheterization, Central Venous","Catheter-Associated Infections","Bacterial Infections","Bacteremia",[240,265],"74% Ethanol with 10% 2-propanol",{"trials":267,"activeCount":50},[],{"intervention":265,"totalTrials":46,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":284},{"trials":271,"activeCount":50},[],{"trials":273,"activeCount":50},[],{"trials":275,"activeCount":50},[],{"trials":277,"activeCount":50},[],{"trials":279,"activeCount":50},[280],{"nctId":253,"briefTitle":254,"status":105,"phases":281,"completion":256,"start":257,"enrollment":258,"conditions":282,"interventions":283},[42],[260,261,262,263],[240,265],{"trials":285,"activeCount":50},[],{"intervention":287,"totalTrials":46,"cells":288},"Syntocinon 24 IU",{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":309},{"trials":290,"activeCount":50},[],{"trials":292,"activeCount":50},[],{"trials":294,"activeCount":50},[],{"trials":296,"activeCount":50},[],{"trials":298,"activeCount":50},[299],{"nctId":300,"briefTitle":301,"status":105,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT01216605","Oxytocin and Emotion Recognition",[42],"2010-01","2009-11",56,[307],"Health",[287],{"trials":310,"activeCount":50},[],{"intervention":312,"totalTrials":46,"cells":313},"Thyroxin, Triiodothyronine",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":336},{"trials":315,"activeCount":50},[],{"trials":317,"activeCount":50},[],{"trials":319,"activeCount":50},[],{"trials":321,"activeCount":50},[],{"trials":323,"activeCount":50},[324],{"nctId":325,"briefTitle":326,"status":105,"phases":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":335},"NCT00360074","Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation",[42],"2007-04","2004-02",25,[332,333,334],"Secondary Hypothyroidism","Hypopituitarism","Hyperlipidemias",[312],{"trials":337,"activeCount":50},[],{"intervention":339,"totalTrials":46,"cells":340},"Olanzapine",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":358,"NA":360},{"trials":342,"activeCount":50},[],{"trials":344,"activeCount":50},[],{"trials":346,"activeCount":50},[],{"trials":348,"activeCount":50},[349],{"nctId":350,"briefTitle":351,"status":352,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":50,"conditions":356,"interventions":357},"NCT00273624","Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial","WITHDRAWN",[41],"2009-12","2005-06",[18],[339],{"trials":359,"activeCount":50},[],{"trials":361,"activeCount":50},[],{"intervention":363,"totalTrials":46,"cells":364},"Arm A",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":385,"NA":387},{"trials":366,"activeCount":50},[],{"trials":368,"activeCount":50},[],{"trials":370,"activeCount":50},[],{"trials":372,"activeCount":50},[373],{"nctId":374,"briefTitle":375,"status":376,"phases":377,"primaryCompletion":378,"completion":379,"start":193,"enrollment":380,"conditions":381,"interventions":383},"NCT02531841","High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma","UNKNOWN",[41],"2017-11","2019-12",250,[382],"Diffuse Large B-cell-lymphoma",[363,384],"Arm B",{"trials":386,"activeCount":50},[],{"trials":388,"activeCount":50},[],{"intervention":384,"totalTrials":46,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":403,"NA":405},{"trials":392,"activeCount":50},[],{"trials":394,"activeCount":50},[],{"trials":396,"activeCount":50},[],{"trials":398,"activeCount":50},[399],{"nctId":374,"briefTitle":375,"status":376,"phases":400,"primaryCompletion":378,"completion":379,"start":193,"enrollment":380,"conditions":401,"interventions":402},[41],[382],[363,384],{"trials":404,"activeCount":50},[],{"trials":406,"activeCount":50},[],{"intervention":408,"totalTrials":46,"cells":409},"Intravenous injection of heparin",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":436,"NA":438},{"trials":411,"activeCount":50},[],{"trials":413,"activeCount":50},[],{"trials":415,"activeCount":50},[],{"trials":417,"activeCount":50},[418],{"nctId":419,"briefTitle":420,"status":421,"phases":422,"start":423,"enrollment":424,"conditions":425,"interventions":431},"NCT00637468","EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye","TERMINATED",[41],"2002-09",84,[426,427,428,429,430],"Retinal Artery Occlusion","Fibrinolysis","Visual Acuity","Stroke","Hemodilution",[408,432,433,434,435],"Intravenous injection of acetazolamide","Topical use of beta-blocker","Isovolaemic haemodilution","Acetylsalicylic acid",{"trials":437,"activeCount":50},[],{"trials":439,"activeCount":50},[],{"intervention":432,"totalTrials":46,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":454,"NA":456},{"trials":443,"activeCount":50},[],{"trials":445,"activeCount":50},[],{"trials":447,"activeCount":50},[],{"trials":449,"activeCount":50},[450],{"nctId":419,"briefTitle":420,"status":421,"phases":451,"start":423,"enrollment":424,"conditions":452,"interventions":453},[41],[426,427,428,429,430],[408,432,433,434,435],{"trials":455,"activeCount":50},[],{"trials":457,"activeCount":50},[],{"intervention":433,"totalTrials":46,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":472,"NA":474},{"trials":461,"activeCount":50},[],{"trials":463,"activeCount":50},[],{"trials":465,"activeCount":50},[],{"trials":467,"activeCount":50},[468],{"nctId":419,"briefTitle":420,"status":421,"phases":469,"start":423,"enrollment":424,"conditions":470,"interventions":471},[41],[426,427,428,429,430],[408,432,433,434,435],{"trials":473,"activeCount":50},[],{"trials":475,"activeCount":50},[],{"intervention":434,"totalTrials":46,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":484,"PHASE4":490,"NA":492},{"trials":479,"activeCount":50},[],{"trials":481,"activeCount":50},[],{"trials":483,"activeCount":50},[],{"trials":485,"activeCount":50},[486],{"nctId":419,"briefTitle":420,"status":421,"phases":487,"start":423,"enrollment":424,"conditions":488,"interventions":489},[41],[426,427,428,429,430],[408,432,433,434,435],{"trials":491,"activeCount":50},[],{"trials":493,"activeCount":50},[],{"intervention":435,"totalTrials":46,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":508,"NA":510},{"trials":497,"activeCount":50},[],{"trials":499,"activeCount":50},[],{"trials":501,"activeCount":50},[],{"trials":503,"activeCount":50},[504],{"nctId":419,"briefTitle":420,"status":421,"phases":505,"start":423,"enrollment":424,"conditions":506,"interventions":507},[41],[426,427,428,429,430],[408,432,433,434,435],{"trials":509,"activeCount":50},[],{"trials":511,"activeCount":50},[],{"intervention":513,"totalTrials":46,"cells":514},"FK506 0.06%",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":530,"NA":532},{"trials":516,"activeCount":50},[],{"trials":518,"activeCount":50},[],{"trials":520,"activeCount":50},[],{"trials":522,"activeCount":50},[523],{"nctId":524,"briefTitle":525,"status":421,"phases":526,"conditions":527,"interventions":529},"NCT00463723","Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty",[40,41],[528],"Penetrating Keratoplasty",[513],{"trials":531,"activeCount":50},[],{"trials":533,"activeCount":50},[],{"intervention":535,"totalTrials":46,"cells":536},"Aripiprazole",{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":551,"NA":553},{"trials":538,"activeCount":50},[],{"trials":540,"activeCount":50},[],{"trials":542,"activeCount":50},[],{"trials":544,"activeCount":50},[545],{"nctId":546,"briefTitle":547,"status":352,"phases":548,"primaryCompletion":304,"completion":304,"start":355,"enrollment":50,"conditions":549,"interventions":550},"NCT00276978","Aripiprazole Augmentation Therapy in Treatment-resistant Depression",[41],[18],[535],{"trials":552,"activeCount":50},[],{"trials":554,"activeCount":50},[],{"intervention":556,"totalTrials":46,"cells":557},"Escitalopram",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":577,"NA":579},{"trials":559,"activeCount":50},[],{"trials":561,"activeCount":50},[],{"trials":563,"activeCount":50},[],{"trials":565,"activeCount":50},[566],{"nctId":567,"briefTitle":568,"status":376,"phases":569,"primaryCompletion":570,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":576},"NCT00837564","Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression",[41],"2010-04","2011-04","2009-02",60,[575],"Chronic Depression",[556],{"trials":578,"activeCount":50},[],{"trials":580,"activeCount":50},[],{"intervention":582,"totalTrials":46,"cells":583},"Somatostatin",{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":602,"NA":604},{"trials":585,"activeCount":50},[],{"trials":587,"activeCount":50},[],{"trials":589,"activeCount":50},[],{"trials":591,"activeCount":50},[592],{"nctId":593,"briefTitle":594,"status":105,"phases":595,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":601},"NCT00386984","Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma",[41],"2003-02","1999-10",108,[600],"Carcinoma, Hepatocellular",[582],{"trials":603,"activeCount":50},[],{"trials":605,"activeCount":50},[],{"intervention":607,"totalTrials":11,"cells":608},"methotrexate",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":610,"activeCount":50},[],{"trials":612,"activeCount":50},[],{"trials":614,"activeCount":50},[615,630],{"nctId":616,"briefTitle":617,"status":376,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT00647049","Freiburg ZNS-NHL Study",[40],"2013-05","2013-08","2007-01",78,[624],"Primary Non Hodgkin Lymphoma of the Central Nervous System",[607,626,627,628,629],"Rituximab","Cytarabine","Thiotepa","Carmustin",{"nctId":631,"briefTitle":632,"status":376,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":305,"conditions":637,"interventions":638},"NCT00989352","Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma",[40],"2011-06","2011-09","2009-09",[624],[639,640,641,626],"Methotrexate","Lomustine","Procarbazine",{"trials":643,"activeCount":50},[],{"trials":645,"activeCount":50},[],{"trials":647,"activeCount":50},[],{"intervention":626,"totalTrials":11,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":651,"activeCount":50},[],{"trials":653,"activeCount":50},[],{"trials":655,"activeCount":50},[656,660],{"nctId":616,"briefTitle":617,"status":376,"phases":657,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":658,"interventions":659},[40],[624],[607,626,627,628,629],{"nctId":631,"briefTitle":632,"status":376,"phases":661,"primaryCompletion":634,"completion":635,"start":636,"enrollment":305,"conditions":662,"interventions":663},[40],[624],[639,640,641,626],{"trials":665,"activeCount":50},[],{"trials":667,"activeCount":50},[],{"trials":669,"activeCount":50},[],{"intervention":671,"totalTrials":46,"cells":672},"Decitabine 15 mg\u002Fm2 i.v.",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":674,"activeCount":50},[],{"trials":676,"activeCount":50},[],{"trials":678,"activeCount":50},[679],{"nctId":680,"briefTitle":681,"status":105,"phases":682,"primaryCompletion":572,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":687},"NCT00866073","Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia",[40],"2009-03","2003-04",238,[24],[671],{"trials":689,"activeCount":50},[],{"trials":691,"activeCount":50},[],{"trials":693,"activeCount":50},[],{"intervention":695,"totalTrials":46,"cells":696},"Methylphenidate",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":698,"activeCount":50},[],{"trials":700,"activeCount":50},[],{"trials":702,"activeCount":50},[703],{"nctId":704,"briefTitle":705,"status":105,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":712},"NCT00772161","Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)",[39,40],"2008-12","2008-10",24,[711],"Attention Deficit Hyperactivity Disorder",[695],{"trials":714,"activeCount":50},[],{"trials":716,"activeCount":50},[],{"trials":718,"activeCount":50},[],{"intervention":627,"totalTrials":46,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":722,"activeCount":50},[],{"trials":724,"activeCount":50},[],{"trials":726,"activeCount":50},[727],{"nctId":616,"briefTitle":617,"status":376,"phases":728,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":729,"interventions":730},[40],[624],[607,626,627,628,629],{"trials":732,"activeCount":50},[],{"trials":734,"activeCount":50},[],{"trials":736,"activeCount":50},[],{"intervention":628,"totalTrials":46,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":740,"activeCount":50},[],{"trials":742,"activeCount":50},[],{"trials":744,"activeCount":50},[745],{"nctId":616,"briefTitle":617,"status":376,"phases":746,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":747,"interventions":748},[40],[624],[607,626,627,628,629],{"trials":750,"activeCount":50},[],{"trials":752,"activeCount":50},[],{"trials":754,"activeCount":50},[],{"intervention":629,"totalTrials":46,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":758,"activeCount":50},[],{"trials":760,"activeCount":50},[],{"trials":762,"activeCount":50},[763],{"nctId":616,"briefTitle":617,"status":376,"phases":764,"primaryCompletion":619,"completion":620,"start":621,"enrollment":622,"conditions":765,"interventions":766},[40],[624],[607,626,627,628,629],{"trials":768,"activeCount":50},[],{"trials":770,"activeCount":50},[],{"trials":772,"activeCount":50},[],{"intervention":640,"totalTrials":46,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":776,"activeCount":50},[],{"trials":778,"activeCount":50},[],{"trials":780,"activeCount":50},[781],{"nctId":631,"briefTitle":632,"status":376,"phases":782,"primaryCompletion":634,"completion":635,"start":636,"enrollment":305,"conditions":783,"interventions":784},[40],[624],[639,640,641,626],{"trials":786,"activeCount":50},[],{"trials":788,"activeCount":50},[],{"trials":790,"activeCount":50},[],{"intervention":641,"totalTrials":46,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":794,"activeCount":50},[],{"trials":796,"activeCount":50},[],{"trials":798,"activeCount":50},[799],{"nctId":631,"briefTitle":632,"status":376,"phases":800,"primaryCompletion":634,"completion":635,"start":636,"enrollment":305,"conditions":801,"interventions":802},[40],[624],[639,640,641,626],{"trials":804,"activeCount":50},[],{"trials":806,"activeCount":50},[],{"trials":808,"activeCount":50},[],{"intervention":810,"totalTrials":46,"cells":811},"Vorinostat",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":813,"activeCount":50},[],{"trials":815,"activeCount":50},[],{"trials":817,"activeCount":50},[818],{"nctId":819,"briefTitle":820,"status":105,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":827},"NCT01394354","Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)",[39,40],"2015-12","2011-08",34,[826],"Multiple Myeloma in Relapse",[810,828,829,830],"Bortezomib","Doxorubicin","Dexamethasone",{"trials":832,"activeCount":50},[],{"trials":834,"activeCount":50},[],{"trials":836,"activeCount":50},[],{"intervention":828,"totalTrials":46,"cells":838},{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":849,"PHASE4":851,"NA":853},{"trials":840,"activeCount":50},[],{"trials":842,"activeCount":50},[],{"trials":844,"activeCount":50},[845],{"nctId":819,"briefTitle":820,"status":105,"phases":846,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":847,"interventions":848},[39,40],[826],[810,828,829,830],{"trials":850,"activeCount":50},[],{"trials":852,"activeCount":50},[],{"trials":854,"activeCount":50},[],{"intervention":829,"totalTrials":46,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":858,"activeCount":50},[],{"trials":860,"activeCount":50},[],{"trials":862,"activeCount":50},[863],{"nctId":819,"briefTitle":820,"status":105,"phases":864,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":865,"interventions":866},[39,40],[826],[810,828,829,830],{"trials":868,"activeCount":50},[],{"trials":870,"activeCount":50},[],{"trials":872,"activeCount":50},[],{"intervention":830,"totalTrials":46,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":876,"activeCount":50},[],{"trials":878,"activeCount":50},[],{"trials":880,"activeCount":50},[881],{"nctId":819,"briefTitle":820,"status":105,"phases":882,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":883,"interventions":884},[39,40],[826],[810,828,829,830],{"trials":886,"activeCount":50},[],{"trials":888,"activeCount":50},[],{"trials":890,"activeCount":50},[],{"intervention":892,"totalTrials":46,"cells":893},"Basiliximab",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":895,"activeCount":50},[],{"trials":897,"activeCount":50},[],{"trials":899,"activeCount":50},[900],{"nctId":901,"briefTitle":902,"status":105,"phases":903,"completion":904,"start":905,"conditions":906,"interventions":907},"NCT00409656","Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients",[40],"2005-12","2003-12",[26],[892],{"trials":909,"activeCount":50},[],{"trials":911,"activeCount":50},[],{"trials":913,"activeCount":50},[],{"intervention":915,"totalTrials":46,"cells":916},"Decitabine",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":918,"activeCount":50},[],{"trials":920,"activeCount":50},[],{"trials":922,"activeCount":50},[923],{"nctId":924,"briefTitle":925,"status":105,"phases":926,"primaryCompletion":927,"completion":928,"start":823,"enrollment":929,"conditions":930,"interventions":931},"NCT00867672","Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia",[40],"2015-02","2016-02",204,[24],[915,932,933],"VPA","ATRA",{"trials":935,"activeCount":50},[],{"trials":937,"activeCount":50},[],{"trials":939,"activeCount":50},[],{"intervention":932,"totalTrials":46,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":943,"activeCount":50},[],{"trials":945,"activeCount":50},[],{"trials":947,"activeCount":50},[948],{"nctId":924,"briefTitle":925,"status":105,"phases":949,"primaryCompletion":927,"completion":928,"start":823,"enrollment":929,"conditions":950,"interventions":951},[40],[24],[915,932,933],{"trials":953,"activeCount":50},[],{"trials":955,"activeCount":50},[],{"trials":957,"activeCount":50},[],{"intervention":933,"totalTrials":46,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":961,"activeCount":50},[],{"trials":963,"activeCount":50},[],{"trials":965,"activeCount":50},[966],{"nctId":924,"briefTitle":925,"status":105,"phases":967,"primaryCompletion":927,"completion":928,"start":823,"enrollment":929,"conditions":968,"interventions":969},[40],[24],[915,932,933],{"trials":971,"activeCount":50},[],{"trials":973,"activeCount":50},[],{"trials":975,"activeCount":50},[],{"intervention":977,"totalTrials":46,"cells":978},"somatotropin",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":980,"activeCount":50},[],{"trials":982,"activeCount":50},[],{"trials":984,"activeCount":50},[985],{"nctId":986,"briefTitle":987,"status":105,"phases":988,"primaryCompletion":989,"completion":823,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT00533221","Pilot Study of Growth Hormon to Treat SMA Typ II and III",[40],"2010-02","2007-10",20,[993],"Muscular Atrophy, Spinal",[977],{"trials":996,"activeCount":50},[],{"trials":998,"activeCount":50},[],{"trials":1000,"activeCount":50},[],{"intervention":1002,"totalTrials":46,"cells":1003},"Radium-223 dichloride",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1021,"PHASE4":1023,"NA":1025},{"trials":1005,"activeCount":50},[],{"trials":1007,"activeCount":50},[],{"trials":1009,"activeCount":50},[1010],{"nctId":1011,"briefTitle":1012,"status":376,"phases":1013,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1020},"NCT02484339","Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)",[40],"2016-12","2017-12","2014-12",274,[1019],"Prostate Carcinoma",[1002],{"trials":1022,"activeCount":50},[],{"trials":1024,"activeCount":50},[],{"trials":1026,"activeCount":50},[],{"intervention":1028,"totalTrials":46,"cells":1029},"Ziprasidone Hydrochloride",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1031,"activeCount":50},[],{"trials":1033,"activeCount":50},[],{"trials":1035,"activeCount":50},[1036],{"nctId":1037,"briefTitle":1038,"status":105,"phases":1039,"primaryCompletion":194,"completion":194,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1045},"NCT00676429","Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders",[40],"2006-07",51,[1043,1044],"Conduct Disorder","Oppositional Defiant Disorder",[1028],{"trials":1047,"activeCount":50},[],{"trials":1049,"activeCount":50},[],{"trials":1051,"activeCount":50},[],{"intervention":1053,"totalTrials":46,"cells":1054},"Everolimus and mycophenolate sodium",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1056,"activeCount":50},[],{"trials":1058,"activeCount":50},[],{"trials":1060,"activeCount":50},[1061],{"nctId":1062,"briefTitle":1063,"status":376,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1071},"NCT00856505","Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation",[39,40],"2010-03","2011-03","2008-03",38,[1070],"Hematologic Diseases",[1053],{"trials":1073,"activeCount":50},[],{"trials":1075,"activeCount":50},[],{"trials":1077,"activeCount":50},[],{"intervention":1079,"totalTrials":46,"cells":1080},"ranibizumab",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1082,"activeCount":50},[],{"trials":1084,"activeCount":50},[],{"trials":1086,"activeCount":50},[1087],{"nctId":1088,"briefTitle":1089,"status":105,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT02134457","Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity",[40],"2017-01","2014-08",19,[30],[1079],{"trials":1097,"activeCount":50},[],{"trials":1099,"activeCount":50},[],{"trials":1101,"activeCount":50},[],{"intervention":1103,"totalTrials":46,"cells":1104},"LMB-9 immunotoxin",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1106,"activeCount":50},[],{"trials":1108,"activeCount":50},[1109],{"nctId":1110,"briefTitle":1111,"status":376,"phases":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1120},"NCT00010270","LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer",[39],"2001-04",50,[1116,1117,1118,1119],"Colorectal Cancer","Esophageal Cancer","Gastric Cancer","Pancreatic Cancer",[1103],{"trials":1122,"activeCount":50},[],{"trials":1124,"activeCount":50},[],{"trials":1126,"activeCount":50},[],{"trials":1128,"activeCount":50},[],{"intervention":1130,"totalTrials":46,"cells":1131},"mistletoe preparations",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1145,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1133,"activeCount":50},[],{"trials":1135,"activeCount":50},[1136],{"nctId":1137,"briefTitle":1138,"status":105,"phases":1139,"primaryCompletion":194,"completion":194,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1144},"NCT01378702","Safety and Immunological Effects of Two Mistletoe Preparations in Healthy Volunteers",[39],"2008-01",71,[1143],"Healthy Volunteers",[1130],{"trials":1146,"activeCount":50},[],{"trials":1148,"activeCount":50},[],{"trials":1150,"activeCount":50},[],{"trials":1152,"activeCount":50},[],{"intervention":1154,"totalTrials":46,"cells":1155},"polymerase chain reaction",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1157,"activeCount":50},[],{"trials":1159,"activeCount":50},[],{"trials":1161,"activeCount":50},[],{"trials":1163,"activeCount":50},[],{"trials":1165,"activeCount":50},[],{"trials":1167,"activeCount":50},[1168],{"nctId":1169,"briefTitle":1170,"status":105,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":621,"enrollment":1173,"conditions":1174,"interventions":1179},"NCT00499070","Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment",[],"2012-08",119,[1175,1176,22,1177,1178],"Dyskeratosis Congenita","Fanconi Anemia","Pearson Marrow-pancreas Syndrome","Shwachman-diamond Syndrome",[1154],{"intervention":1181,"totalTrials":46,"cells":1182},"terlipressin or noradrenalin plus albumin",{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1184,"activeCount":50},[],{"trials":1186,"activeCount":50},[],{"trials":1188,"activeCount":50},[],{"trials":1190,"activeCount":50},[],{"trials":1192,"activeCount":50},[],{"trials":1194,"activeCount":50},[1195],{"nctId":1196,"briefTitle":1197,"status":105,"phases":1198,"primaryCompletion":1199,"completion":1199,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1205},"NCT06161766","Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease",[],"2024-12-31","2024-03-03",490,[15,1203,1204],"Hepato-Renal Syndrome","Chronic Kidney Diseases",[1181],{"intervention":1207,"totalTrials":46,"cells":1208},"Sertraline",{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1210,"activeCount":50},[],{"trials":1212,"activeCount":50},[],{"trials":1214,"activeCount":50},[],{"trials":1216,"activeCount":50},[],{"trials":1218,"activeCount":50},[],{"trials":1220,"activeCount":50},[1221],{"nctId":1222,"briefTitle":1223,"status":105,"phases":1224,"completion":1225,"start":904,"enrollment":9,"conditions":1226,"interventions":1228},"NCT00263133","Modulation of Visually Evoked Potentials by an Antidepressant",[43],"2006-01",[1227],"Depression",[1207]]